Compare NG & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NG | ABCL |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | 2002 | 2020 |
| Metric | NG | ABCL |
|---|---|---|
| Price | $8.29 | $11.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $12.22 | $8.40 |
| AVG Volume (30 Days) | 5.0M | ★ 9.1M |
| Earning Date | 04-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $5.08 | $2.75 |
| 52 Week High | $14.40 | $12.58 |
| Indicator | NG | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 62.27 |
| Support Level | $8.22 | $3.39 |
| Resistance Level | $8.75 | $12.58 |
| Average True Range (ATR) | 0.46 | 0.74 |
| MACD | -0.12 | -0.15 |
| Stochastic Oscillator | 34.76 | 50.77 |
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.